Stock INDV INDIVIOR PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Indivior PLC

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 11:35:24 2024-05-23 am EDT 		5-day change 1st Jan Change
1,328 GBX +0.23% Intraday chart for Indivior PLC -1.78% +12.07%
May. 23 Indivior Confirms FY24 Outlook MT
May. 23 Transcript : Indivior PLC - Shareholder/Analyst Call

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 377.9 1,091 2,441 3,057 2,060 2,277 - -
Enterprise Value (EV) 1 -443.1 518.3 1,581 2,523 1,983 1,996 1,694 1,355
P/E ratio 2.87 x -7.44 x 12.9 x -58.9 x 1,508 x 9.08 x 6.97 x 5.34 x
Yield - - - - - - - -
Capitalization / Revenue 0.48 x 1.69 x 3.09 x 3.39 x 1.88 x 1.8 x 1.6 x 1.46 x
EV / Revenue -0.56 x 0.8 x 2 x 2.8 x 1.81 x 1.58 x 1.19 x 0.87 x
EV / EBITDA -2 x 4.89 x 7.83 x 11.2 x 6.88 x 5.36 x 3.75 x 2.53 x
EV / FCF -2.97 x -2.63 x 4.67 x -11.1 x -4.8 x 7.98 x 6.06 x 2.86 x
FCF Yield -33.6% -38% 21.4% -9% -20.8% 12.5% 16.5% 35%
Price to Book - - - 61.1 x - 10.5 x 4.03 x 2.34 x
Nbr of stocks (in thousands) 146,153 146,701 140,437 136,489 136,551 134,887 - -
Reference price 2 2.586 7.439 17.38 22.40 15.08 16.88 16.88 16.88
Announcement Date 2/13/20 2/18/21 2/16/22 2/16/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 785 647 791 901 1,093 1,262 1,423 1,559
EBITDA 1 222 106 202 225 288 372.4 451.2 534.5
EBIT 1 202 88 187 212 269 346.4 419 504
Operating Margin 25.73% 13.6% 23.64% 23.53% 24.61% 27.44% 29.45% 32.33%
Earnings before Tax (EBT) 1 180 -173 190 -95 1 332 407.2 543
Net income 1 134 -148 205 -53 2 267.8 341.2 439.8
Net margin 17.07% -22.87% 25.92% -5.88% 0.18% 21.22% 23.98% 28.21%
EPS 2 0.9000 -1.000 1.350 -0.3800 0.0100 1.860 2.423 3.160
Free Cash Flow 1 149 -197 339 -227 -413 250.2 279.4 473.8
FCF margin 18.98% -30.45% 42.86% -25.19% -37.79% 19.83% 19.64% 30.39%
FCF Conversion (EBITDA) 67.12% - 167.82% - - 67.19% 61.92% 88.64%
FCF Conversion (Net income) 111.19% - 165.37% - - 93.45% 81.89% 107.73%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/13/20 2/18/21 2/16/22 2/16/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 222 - 221 253 276 271 293 284 305.6 328.2 344.4 358.8 362.5
EBITDA 1 - - - - - - - 77 78 98.5 112.9 112.5 109
EBIT 1 32 - - 71 71 60 66 70 78 93.75 105 107.5 107
Operating Margin 14.41% - - 28.06% 25.72% 22.14% 22.53% 24.65% 25.52% 28.57% 30.47% 29.96% 29.52%
Earnings before Tax (EBT) 1 - - - - 62 -181 61 63 75.6 91.35 102.6 101.9 101.4
Net income 1 - 41 - 44 39 -135 54 47 58.65 70.55 79.6 78.4 78.1
Net margin - - - 17.39% 14.13% -49.82% 18.43% 16.55% 19.19% 21.5% 23.11% 21.85% 21.54%
EPS 2 - 0.3000 - 0.3100 - -0.9800 0.3800 0.3400 0.4250 0.5200 0.5850 0.5800 0.5800
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/16/22 4/28/22 7/28/22 4/27/23 7/27/23 11/9/23 2/22/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 821 573 860 534 77 281 583 922
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 149 -197 339 -227 -413 250 279 474
ROE (net income / shareholders' equity) - - - 133% 875% 206% 94.9% 56%
ROA (Net income/ Total Assets) - - - - - 14.2% 15.5% 14.8%
Assets 1 - - - - - 1,885 2,208 2,979
Book Value Per Share 2 - - - 0.3700 - 1.600 4.190 7.220
Cash Flow per Share 2 - - - - - 1.990 2.690 2.560
Capex 1 7 4 14 5 8 6.71 20.3 8.96
Capex / Sales 0.89% 0.62% 1.77% 0.55% 0.73% 0.53% 1.43% 0.57%
Announcement Date 2/13/20 2/18/21 2/16/22 2/16/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Indivior PLC

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.88 USD
Average target price
30.66 USD
Spread / Average Target
+81.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
INDIVIOR PLC Stock Indivior PLC
+12.07% 2.28B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+7.70% 8.74B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-15.14% 4.94B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+50.73% 4.7B
YUHAN CORPORATION Stock Yuhan Corporation
+4.36% 3.98B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-26.13% 2.28B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+16.45% 2.14B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-33.59% 2.12B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
-4.04% 1.53B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INDV Stock
  4. Financials Indivior PLC